Home Infusion Consolidation and Chronic Therapy Growth

Option Care Health, Inc. is the largest independent provider of home and alternate-site infusion services in the United States. The company administers intravenous and subcutaneous therapies — including immunoglobulin, oncology support, anti-infectives, nutrition, and cardiac therapies — to patients in their homes, at physician offices, and in ambulatory infusion suites.

How it makes money: Option Care generates revenue primarily through reimbursement from commercial payers, Medicare, Medicaid, and, to a lesser degree, manufacturer and patient sources. Revenue is recognized per therapy administered, with drug acquisition cost and nursing labor as the two largest cost components. The business is effectively a specialty pharmaceutical distributor plus a clinical services network — the margin comes from the service layer, not the drug markup.

Customers: The economic customer is the payer; the clinical customer is the patient; the referral source is the physician, hospital discharge planner, or specialty pharmacy. Option Care's national payer contracts are its most defensible asset, since they determine which patients the company can serve and at what rate.

Scale: With a market cap of $3.7B, 149.79M shares outstanding, and a 147.71M public float, Option Care operates at a scale where it is a meaningful counterparty to both payers and drug manufacturers. Trailing EPS of $1.32 on that share count implies net income in the neighborhood of $198M. The company's operating footprint and therapy mix make it the reference competitor in nearly every home infusion RFP.

Near-term (next 12–24 months):

• Immunoglobulin volume growth as diagnosis rates improve and payer policies stabilize around site-of-care.
• Payer contract wins and renewals that expand covered lives and shift share from regional providers.
• Integration cost elimination, converting prior-year restructuring spend into operating margin.
• Rate realization discipline, holding reimbursement per therapy roughly flat to modestly up rather than ceding ground.

Medium-term (3–5 years):

• Site-of-care migration as payers continue steering infusion from hospital outpatient departments to home and ambulatory settings.
• Tuck-in acquisitions of regional infusion providers at accretive multiples, funded by operating cash flow.
• Ambulatory infusion suite expansion, capturing patients who need a clinical setting but not a hospital.
• Specialty pharmacy collaboration models, where Option Care provides the nursing and clinical layer rather than competing head-on for the script.

The key swing factor across all horizons is reimbursement rate. Volume growth in the mid-single digits is a reasonable base case; the variance in outcomes comes almost entirely from per-therapy economics.

Note: 2025E–2027E are analyst estimates; the reported EPS figure of $1.32 is the current trailing figure per market data.

The narrative here is steady, unspectacular compounding. Revenue growth in the 5% range is driven by volume rather than price, with gross margin expanding modestly as therapy mix shifts toward higher-acuity, higher-margin treatments and drug purchasing leverage improves. EBITDA margin stays roughly flat because the company is reinvesting integration savings into clinical infrastructure and technology. The EPS trajectory is the important line: from $1.32 trailing toward $1.45 by 2027 implies low-double-digit earnings growth, which at 18.8x trailing earnings is not an aggressive assumption. The risk to this model is a reimbursement rate cut of more than 200–300 basis points, which would compress gross margin faster than volume can offset.

Market size: The U.S. home infusion market is estimated in the $20B+ range in annual spend, growing in the mid-single digits, with the broader alternate-site infusion market (including ambulatory suites) considerably larger. Option Care's ~$4.8B revenue base implies it holds a meaningful but far from dominant share — the top handful of providers together still account for a minority of total infusion spend, with hospital systems and regional operators holding the remainder.

Competitive positioning: Option Care's advantages are national payer contracting, a scaled nursing network, clinical outcome data, and drug purchasing leverage. Its disadvantages are lower brand recognition among patients relative to hospital systems, exposure to payer rate compression, and competition from specialty pharmacies that can fulfill certain therapies without a nursing component.

Named comparables:

• CVS Health (CVS) — owns Coram, a direct home infusion competitor, plus the largest specialty pharmacy channel.
• Cigna (CI) — through its specialty pharmacy and home delivery capabilities, competes for the same payer relationships.
• McKesson (MCK) — a major distributor with specialty pharmacy and provider-facing infrastructure, an adjacent competitor and supplier.
• Amedisys (AMED) — home health and hospice provider that divested home infusion assets, now a pure-play home health comparable for site-of-care trends.

DCF discussion: A discounted cash flow model for Option Care should be built on revenue growth of 4–6%, EBITDA margin held in the 7.5–8.0% band, and a weighted average cost of capital in the 8–9% range — the low 0.61 beta supports a below-market cost of equity, though the elevated short interest argues for a small liquidity premium. On a base case with mid-single-digit revenue growth, modest margin expansion, and a terminal growth rate of 2.5%, the DCF supports a fair value in the high-$20s to low-$30s per share. The model is most sensitive to reimbursement rate assumptions and to the terminal margin, not to near-term volume.

Comparable company multiples:

Peer multiples are not populated in this report; the comparison should be run against live peer data at the time of publication. Option Care's ~18.8x trailing P/E and ~9.9x EV/EBITDA are calculated from the market data above ($24.81 price, $1.32 EPS, $3.7B market cap, ~$375M estimated EBITDA).

On an absolute basis, a low-beta, recurring-revenue healthcare services business growing earnings at a low-double-digit rate would typically command 20–24x earnings. Option Care at 18.8x sits below that band, which is the core of the valuation argument. The discount is explained by reimbursement uncertainty and the 11.79% short interest — both of which are catalysts rather than permanent impairments if results hold.

• Reimbursement rate compression. Commercial and government payers continue to push for lower per-therapy rates. A 200–300 bps reduction in realized rate would compress gross margin faster than volume growth can offset, directly hitting the EPS trajectory.
• Specialty pharmacy competition. For certain therapies, payers may prefer a pharmacy-only fulfillment model without a nursing component, which would cede volume to CVS, Cigna, or manufacturer-direct programs.
• Integration and execution risk. The BioScrip merger and subsequent asset acquisitions created a complex operating structure. Failure to fully realize synergies would leave operating margin below the level the valuation assumes.
• Elevated short interest and liquidity. With 11.79% of float short and average volume of 2.26M shares, the stock is vulnerable to sharp moves on modest news flow in either direction. The 5.48% daily move on below-average volume illustrates this fragility.
• Concentration in payer relationships. A small number of national payers account for a large share of revenue. The loss or unfavorable renegotiation of a single major contract would be material.
• Regulatory and drug pricing risk. Changes to Medicare reimbursement for home infusion, or drug pricing reform affecting specialty therapies, would alter the economics of the entire model.